Abstract: A method of producing styrene derivatives expressed the general formula (2) by reacting a benzaldehyde derivative expressed by the general formula (1) with dibromomethane under the existence of zinc metal as well as an active chloride for producing various types of oxystyrene which are polymerized monomers as a photoresist material used in a high density integrated circuit process from easily available materials which also can easily be handled: ##STR1## (wherein R indicates a an alkyl group, alkoxyalkyl group, an alkylcarbonyl group, an alkoxycarbonyl group, a 5 or 6-atom heterocylclic groups, or an alkylsilyl group); ##STR2## (wherein R indicates any of the same substituents as those described above.

Abstract: (A) a diacylated dopamine derivative represented by the formula (I): ##STR1## wherein R.sup.1 represents an alkyl group having 3 to 7 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, substituted or unsubstituted phenyl group or a substituted or unsubstituted nitrogen-containing heterocyclic group; and R.sup.2 represents a hydrogen atom or a lower alkyl group; or a salt thereof; and(B) one or more compounds selected from lactic acid esters, fatty acid monoglycerides and higher alcohols; optionally together with(C) an unsaturated fatty acid monohydric alcohol ester. This preparation has a sustained effect, a high skin permeability and a low skin irritativeness.

Abstract: A pharmaceutical preparation for the percutaneous administration comprises eperisone or tolperisone, including salts thereof, and a monoglyceride of an aliphatic acid having 8 to 12 carbon atoms or/and an ester of lactic acid with an aliphatic alcohol having 12 to 18 carbon atoms. It is improved in the percutaneous absorption.

Abstract: A pharmaceutical preparation for the percutaneous administration comprises eperisone or tolperisone, including salts thereof, and a monoglyceride of an aliphatic acid having 8 to 12 carbon atoms or/and an ester of lactic acid with an aliphatic alcohol having 12 to 18 carbon atoms. It is improved in the percutaneous absorption.

Abstract: The present invention relates to a photosensitive member containing a specific bisazo compound described by general structural formula[I] and formed on an electrically conductive substrate; ##STR1## Wherein X is a hydrogen atom, halogen atom, alkyl radical, alkoxi radical, nitro radical or cyano radical; A is a diatomic radical selected from among the following: ##STR2## B is a coupler described by formulae [II] through [VI]; ##STR3## R is a hydrogen atom, halogen atom, alkyl radical, alkoxi radical, nitro radical or cyano radical; and Y is an aromatic carbocyclic residue or aromatic heterocyclic residue, each of which may have a substituent; G is a carbamoyl radical or sulfamoyl radical and may have a substituent; R.sub.1 is a hydrogen atom, alkyl radical, amino radical or carbamoyl radical, each of which may have a substituent, a carboxyl radical or cyano radical; M is an aryl group which may have a substituent, which is improved in photosensitivity and dispersibility.

Abstract: The present invention uses an azo pigment having in the center of an N-oxide heterocyclic structure as a photoelectrical charge-generating material. The pigments are excellent in dispersion stability in a dispersed solution, and enable the provision of a photosensitive member excellent in sensitivity properties.

Abstract: A hollow particulate for gastric medicines and other durable medicines suspendable in the gastric juice and remainable in the stomach for a long period of time is provided which has been prepared by dissolving ethylcellulose in a lower chlorinated hydrocarbon, or a mixed solution of the lower chlorinated hydrocarbon and a lower chlorofluorinated hydrocarbon and/or water, so that the concentration of ethylcellulose is 0.5 - 4% by weight on the basis of the total weight of the resulting solution, and then spray-drying the solution at an inlet temperature of higher than 50.degree. C.

Abstract: A solid therapeutic preparation for gastric diseases, remaining in stomach for a long period of time and gradually releasing pharmacologically active ingredient contained therein into gastric juice while remaining in stomach, is provided which has been prepared by impregnation of the active ingredient together with other suitable additives into a body of empty globular shell or a granular lump in small size of the material having high buoyancy. The persisting effect of the active ingredient in stomach is thus attained.